Summit Therapeutics: The Conference Call Scheduled After Tomorrow's Close

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Summit typically reports after market close, meaning Day 0 reflects anticipatory trading before results are known, while Day +1 captures the market's first full reaction to the actual numbers.

Summit's post-earnings price behavior has been characterized by significant volatility, with an average absolute Day 0 move of 5.80% and Day +1 move of 7.42%. The most dramatic reactions came during the massive miss quarters—the stock plunged 24.91% the day after the April 2026 report and dropped 14.83% on Day 0 of the February 2025 release. More recently, the stock showed relative stability around the February 2026 earnings, with minimal movement in either direction.

The historical pattern suggests investors should brace for potential double-digit swings, particularly if the company delivers another significant surprise in either direction. The 9.87% average Day 0 range and 9.63% Day +1 range indicate substantial intraday volatility regardless of the ultimate directional move, reflecting the binary nature of biotech earnings where pipeline updates can trigger sharp reassessments of value.

Part 2.2: Options Market Expected Move

The options market is pricing a 5.77% expected move through Friday's expiration, implying a range of $13.89 to $15.59. This sits below the stock's average historical Day 0 move of 5.80% and well below the 7.42% average Day +1 move, suggesting options traders may be underpricing the potential volatility based on Summit's track record of delivering significant post-earnings swings.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Summit, with the consensus rating at 3.89 (approaching Buy territory) and an average price target of $27.98—implying 90% upside from the current $14.74 price. The analyst community is split, with 10 Strong Buys and 6 Holds offset by 2 Strong Sells, reflecting divergent views on the company's clinical pipeline value and execution risk.

The sentiment trend is unchanged over the past month, with the rating distribution holding steady at 10 Strong Buys, 6 Holds, and 2 Strong Sells. This stability suggests analysts are waiting for the upcoming earnings release and any pipeline updates before adjusting their views. The wide range of price targets—from a low of $9.80 to a high of $45.00—underscores the binary nature of biotech investing, where bulls see massive upside from successful clinical programs while bears focus on execution risk and cash burn.

The substantial implied upside to the $27.98 consensus target reflects analyst confidence in Summit's pipeline potential, though investors should note that biotech price targets are heavily dependent on clinical trial outcomes and regulatory decisions that remain uncertain. The unchanged sentiment heading into earnings suggests analysts are taking a wait-and-see approach rather than positioning aggressively ahead of the release.

Part 4: Technical Picture

Summit enters earnings in a deteriorating technical position, with the Barchart Technical Opinion showing a 100% Sell signal—a significant weakening from 80% Sell one week ago and 56% Sell one month ago. This accelerating bearish momentum suggests technical traders are increasingly negative on the stock's near-term prospects.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates immediate downward pressure and negative momentum heading into the earnings release
• Medium-term (100% Sell): Bearish reading confirms weakness extends beyond just near-term trading, suggesting a broader deterioration in the intermediate trend
• Long-term (100% Sell): Maximum sell signal reflects significant weakness in the longer-term trend structure, indicating the stock has lost key technical support levels

Trend Characteristics: The combination of Average strength and Average direction suggests the downtrend is neither exceptionally strong nor weak, but rather a steady, persistent decline that has gained consistency over recent weeks.

The stock is trading at $14.74, positioned below its 20-day ($14.78), 50-day ($15.37), 100-day ($16.94), and 200-day ($17.36) moving averages—a bearish alignment indicating downward pressure across all timeframes. The stock sits above only its 5-day ($14.09) and 10-day ($14.70) moving averages, suggesting a very short-term bounce within a broader downtrend.

The technical setup heading into earnings is decidedly cautionary, with the stock trapped below all major moving averages and showing accelerating sell signals across every timeframe. The 200-day moving average at $17.36 represents overhead resistance nearly 18% above current levels, while the recent failure to hold above the 20-day average suggests even modest rallies are being sold. For a biotech stock prone to large post-earnings moves, this weak technical foundation means any disappointment could trigger an accelerated decline through the $14 level, while even a positive surprise may face resistance from overhead supply. The uniformly bearish technical picture suggests traders have positioned defensively, potentially setting up for either a relief rally on good news or further deterioration on any setback.